Compare Neurocrine Biosciences Inc (NBIX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.7 (market cap $330.98M). The key difference: Neurocrine Biosciences Inc is far larger — about 43.4× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Roundhill S&P 500 0DTE Covered Call Strategy ETF is more actively traded (194,030 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| NBIX | XDTE | |
|---|---|---|
Market Cap | $14.36B | $330.98M |
Volume | 1,237,180 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $44.76 |
52-Week Low | $123.10 | $36.00 |
Typical Hold Time | 23 Days | 54 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
